header
Local cover image
Local cover image
Image from OpenLibrary

Outcome of stem cell transplantation for patients diagnosed with acute myeloid leukemia / Mohammed Hamdi Elsafty ; Supervised Mohamed Abdelmooty Mohamed Samra , Nelly Hassan Aly Eldin , Salem Eid Salem

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Mohammed Hamdi Elsafty , 2014Description: 134 Leaves ; 30cmOther title:
  • استخدام زرع الخلايا الجذعية كعلاج لمرضى اللوكيميا الميلودية الحادة [Added title page title]
Subject(s): Online resources: Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical Summary: The aim of this retrospective study is to clarify, report and evaluate the results of allogeneic stem cell transplantation compared with intensive chemotherapy as post - remission treatment (consolidation treatment) for young adults (18 - 55 years) with acute myeloid leukemia (AML) in the years between 2007 and 2010, in an attempt to determine the more effective approach in maintaining disease remission in Egyptian adult AML patients, and which modality of treatment has less impact on the patient well-being. That will be shown by comparing patients whom were subjected to allogeneic stem cell transplantation to those treated by consolidation chemotherapy as regard disease free survival and overall survival after a 3 - year period of follow up. AML is a disease affecting myeloid hematopoietic stem cells resulting in defective function of all cell lines. This thesis includes 141 patients (males and females) presenting in NCI and Nasser Institute between 2007 and 2010. The median age for patients received consolidation chemotherapy and patients underwent HSCT was 34.5 and 29.4, respectively. M2 was the most common subtype in both groups. All cases reached CR after induction chemotherapy. All cases with available donor underwent HSCT while those without donor received consolidation chemotherapy. HSCT is a better choice for AML patients with available donor
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.M.Sc.2014.Mo.O (Browse shelf(Opens below)) Not for loan 01010110064957000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.M.Sc.2014.Mo.O (Browse shelf(Opens below)) 64957.CD Not for loan 01020110064957000

Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical

The aim of this retrospective study is to clarify, report and evaluate the results of allogeneic stem cell transplantation compared with intensive chemotherapy as post - remission treatment (consolidation treatment) for young adults (18 - 55 years) with acute myeloid leukemia (AML) in the years between 2007 and 2010, in an attempt to determine the more effective approach in maintaining disease remission in Egyptian adult AML patients, and which modality of treatment has less impact on the patient well-being. That will be shown by comparing patients whom were subjected to allogeneic stem cell transplantation to those treated by consolidation chemotherapy as regard disease free survival and overall survival after a 3 - year period of follow up. AML is a disease affecting myeloid hematopoietic stem cells resulting in defective function of all cell lines. This thesis includes 141 patients (males and females) presenting in NCI and Nasser Institute between 2007 and 2010. The median age for patients received consolidation chemotherapy and patients underwent HSCT was 34.5 and 29.4, respectively. M2 was the most common subtype in both groups. All cases reached CR after induction chemotherapy. All cases with available donor underwent HSCT while those without donor received consolidation chemotherapy. HSCT is a better choice for AML patients with available donor

Issued also as CD

There are no comments on this title.

to post a comment.

Click on an image to view it in the image viewer

Local cover image